Thats been out there for awhile now ,but hey,a little further promotion cant hurt
Printable View
good summary.
Maybe to add another point of contention - some seem to feel that a minnow like PEB have little chances to succeed in an heavily regulated market between all the established elephants ... without having a partner able to lift their profile.
Personally (as a small shareholder myself) I think it would feel better seeing them to work together with an well established and experienced partner in their chosen markets. Yes, given that they seem to have a good product it makes you wonder why it seems to be that difficult for them to find one.
Obviously - maybe they are not looking, but than the question springs to mind - WHY?
I believe someone said that they tried but It didnt work out (or they were turned down?)(not sure of the details--maybe someone knows a bit more about that?
One way or the other ,coming in with an established partner does seem to be a much more successful strategy from examples I have seen.
well there goes an easy 500K down the toilet.... https://www.nzx.com/companies/PEB/announcements/264775
I struggle to see value in PEB at the present $230m Market Cap.
In my opinion PEB trades at a massive premium due to being pretty much the only biotech on the NZX, which is small in general.
Sure Cxbladder looks promising but sales are dismal and if this was listed on the ASX I doubt it would have a market cap higher than $100m if $50m.
Looks like the SP went up around 50% at that time so I guess those that sold did lose out at the time and will get some compensation at the present shareholders expense---(Im not going to say anything about the competency of the management) since there has'nt been any problems with announcements before--Oh wait.......
Meanwhile David Darling was admitted to Dunedin hospital with a gunshot wound to......the foot:D
I agree, PEB's Mcap will hold strong as it has supportive shareholders. Undervalued/overvalued depends on the future.
Interesting, could you please give me evidence of the dismal sales?
How many tests have been completed?
What percentage of tests have been recognised as revenue?
How can you possibly gauge sales when you don't even know the price of the product to a user programe?